BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05134948
- Locations
- 🇨🇳
Local Institution - 0001, Beijing, Beijing, China
🇨🇳Local Institution - 0002, Fuzhou, Fujian, China
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
Completed
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 304
- Registration Number
- NCT05123950
- Locations
- 🇺🇸
Medical Data Analytics, Parsippany, New Jersey, United States
A Study of Adjuvant Melanoma Stakeholder Treatment Preferences
Completed
- Conditions
- Melanoma
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 294
- Registration Number
- NCT05115006
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
Phase 2
Completed
- Conditions
- Coronary Artery DiseaseHealthy Participants
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT05093790
- Locations
- 🇬🇧
Local Institution - 0001, Edinburgh, United Kingdom
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT05076175
- Locations
- 🇧🇪
Local Institution - 0056, Brussels, Belgium
🇧🇪Local Institution - 0063, Edegem, Belgium
🇧🇪Local Institution - 0061, Liège, Belgium
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
Completed
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Biological: Nivolumab
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 509
- Registration Number
- NCT05068609
- Locations
- 🇺🇸
Local Institution, Mount Laurel, New Jersey, United States
Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
Completed
- Conditions
- Psoriasis
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 232
- Registration Number
- NCT05065762
- Locations
- 🇺🇸
Local Institution, Morrisville, North Carolina, United States
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT05064436
- Locations
- 🇺🇸
Local Institution - 0001, Ann Arbor, Michigan, United States
🇬🇧Local Institution - 0002, London, United Kingdom
A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT05051553
- Locations
- 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
A Study Evaluating Quality of Life for Participants With Atrial Fibrillation (AF) Following a Bleed (EQUAL-AF)
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2021-09-14
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT05044533
- Locations
- 🇬🇧
Local Institution - 0001, Swansea, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath